ENDRA Life Sciences (NDRA) Net Cash Flow (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Net Cash Flow for 11 consecutive years, with $5.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 2122.43% year-over-year to $5.2 million in Q2 2026; TTM through Jun 2026 was $3.7 million, a 181.26% increase from a year earlier, with the FY2025 full-year figure at -$2.5 million, down 723.68% from the prior year.
• Net Cash Flow was $5.2 million for Q2 2026 at ENDRA Life Sciences, up from -$405903.0 in the prior quarter.
• Over five years, Net Cash Flow peaked at $5.3 million in Q2 2024 and troughed at -$3.3 million in Q3 2022.
• A 5-year average of -$217865.9 and a median of -$1.1 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow plunged 202.76% in 2024 and jumped 2122.43% in 2026, its largest moves.
• Over 5 years, Net Cash Flow stood at -$3.1 million in 2022, then surged by 83.99% to -$500629.0 in 2023, then sank by 202.76% to -$1.5 million in 2024, then surged by 97.91% to -$31672.0 in 2025, then jumped by 16466.14% to $5.2 million in 2026.
• The last three Net Cash Flow figures came in at $5.2 million (Q2 2026), -$405903.0 (Q1 2026), and -$31672.0 (Q4 2025), per Business Quant data.